BPC-157 is a research peptide studied for tissue support that is available through compounding pharmacies when clinically appropriate. Patients can request a telehealth evaluation through the TelosRX Telehealth Portal.
What Is BPC-157?
BPC-157 is a 15-amino-acid peptide derived from a sequence found in gastric juice. It is studied in preclinical research.
It is not an FDA-approved drug. It is available through compounding pharmacies under valid prescription.
Common Discussion Points
Patients often raise BPC-157 during evaluations for:
- Soft tissue recovery research interest
- Gastrointestinal support exploration
- Connective tissue health discussion
- Post-exercise recovery research
A licensed provider determines clinical appropriateness individually.
Pre-PCAC July 2026 Regulatory Context
The Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review peptide compounding categories in July 2026. BPC-157 is among the compounds under regulatory consideration.
Patients interested in compounded BPC-157 should consult a licensed provider while access remains available.
How TelosRX Handles BPC-157
TelosRX is an online-first telehealth service. Patient evaluation is asynchronous, and compounded medications are prepared through our licensed pharmacy partner.
- Step 1: Complete an asynchronous telehealth intake at TelosRX.
- Step 2: A licensed provider reviews your intake.
- Step 3: If clinically appropriate, the provider issues a prescription.
- Step 4: Your compounded preparation ships discreetly to your door.
Important Compliance Information
BPC-157 is not FDA-approved. Compounded preparations are prepared under federal compounding regulations.
Prescriptions require evaluation by a licensed healthcare provider. Approval is not guaranteed. Individual results vary.
TelosRX operates under LegitScript-certified telehealth standards.
Start your private evaluation at TelosRX.